16 September 2026 Unit 2.06/31 Lexington Drive, BELLA VISTA, NSW 2153 Ph: 1300 995 098 • www.cambium.bio • ABN 13 127 035 358 Market Announcements Office ASX Limited Level 27, 39 Martin Place, Sydney NSW Dear Sir/Madam, Re: Late Lodgement of Notices of Ceasing to be a Substantial...
Notice of ceasing to be a substantial holder
Filed with ASX · · 6 pages · English
Release
Earlier from Cambium Bio
- Change in Substantial Holding
- Update - Proposed issue of securities - CMB
- Notification regarding unquoted securities - CMB
- Proposed issue of securities - CMB
- FY26 Appendix 4E and Annual Report
Later from Cambium Bio
- Cambium Bio Secures A$10.85 Million Funding Package
- Cambium Bio Secures A$10.85 Million to Initiate Pivotal Phase 3 Trial of Elate Ocular®, a Potential First-in-Class Biologic for Dry Eye Disease
- Notification of cessation of securities - CMB
- Date of AGM and Closing Date for Director Nominations
- Corporate Presentation - September 2026
Follow Cambium Bio into a list and get an email when it puts out news.
Follow Cambium Bio